Cannabis and Essential Tremor
What the evidence actually says about using cannabis for the most common movement disorder, separating data from hype.
Essential tremor is one of the conditions cannabis is most loudly marketed for, but the actual human evidence is thin. There's a plausible mechanism, decent animal data, and lots of patient self-report, but only a handful of small human trials — and the one rigorous trial of pure CBD was negative. THC-containing products may help some people subjectively, but no one has proven cannabis works better than propranolol or primidone. Treat it as experimental, not established.
Plain-language summary
Essential tremor (ET) is a neurological condition that causes rhythmic shaking, usually in the hands, often worse during action (writing, holding a cup). It is different from Parkinson's tremor, which typically happens at rest. Standard first-line treatments are the beta-blocker propranolol and the anticonvulsant primidone; both help roughly half of patients and both have side effects [1].
Patients frequently ask about cannabis because (a) the endocannabinoid system is involved in motor control, (b) THC and CBD have shown anti-tremor effects in some animal models, and (c) online communities are full of testimonials. The honest scientific picture is much more cautious: there are very few controlled human trials in ET specifically, and the best-designed one — a randomized trial of pure CBD — did not show benefit [2].
This article is not medical advice. Essential tremor can overlap with other neurological conditions, and cannabis interacts with many medications. Talk to a neurologist before changing treatment.
What probably works (strong evidence)
Nothing in the cannabis space meets a 'strong evidence' bar for essential tremor. No data
That is the honest answer. No cannabinoid — not THC, not CBD, not nabiximols, not synthetic analogs — has been shown in adequately powered, replicated, randomized controlled trials to reduce tremor amplitude in essential tremor patients.
If you see a dispensary, influencer, or product page claiming cannabis is a 'proven treatment' for ET, that claim is ahead of the data.
What might work (weak / preliminary evidence)
THC-containing cannabis, subjective improvement. Survey and observational data suggest a meaningful minority of ET patients who try cannabis report subjective tremor reduction. In a 2022 survey study of ET patients, a substantial fraction of users reported benefit, but this is self-report without controlled measurement [3]. Weak / limited
Endocannabinoid system modulation. Preclinical work shows CB1 receptor activity in the cerebellum and inferior olive — brain regions implicated in ET — and cannabinoid agonists reduce tremor in some animal models (e.g., harmaline-induced tremor in rats) [4]. This is mechanistic rationale, not human efficacy. Weak / limited
Anxiety-driven amplification. ET worsens with stress and social anxiety. Cannabis (particularly low-dose THC or CBD) may reduce the anxiety component that amplifies tremor in public settings, without necessarily affecting the underlying tremor. This is plausible but not formally measured in ET trials. Weak / limited
If you try cannabis for ET on these grounds, treat it as a personal experiment, ideally with objective measurement (e.g., video recording standardized tasks before and after).
What doesn't work / negative evidence
Pure CBD alone. A 2022 randomized, double-blind, placebo-controlled crossover trial tested CBD (escalating to 300 mg/day) in adults with essential tremor. The trial was small but well-designed, and CBD did not significantly reduce tremor compared to placebo on standardized rating scales [2]. Strong evidence (for the negative finding within that single trial)
This matters because CBD is what most ET patients try first — it's legal, widely available, and marketed heavily for tremor. The best controlled data we have says, for CBD monotherapy at those doses: no benefit beyond placebo.
'Indica strains are better for tremor.' The indica/sativa labeling system does not reliably predict pharmacology or effects [5]. Any claim that a specific 'indica' is anti-tremor while a 'sativa' isn't is folklore. No data
High-CBD topicals for tremor. No plausible mechanism — tremor is a central nervous system phenomenon and topical CBD does not reach the brain in meaningful concentrations. No data
What we don't know
- Whether THC (the cannabinoid CBD-trial subjects did not receive) reduces tremor objectively. No adequate RCT has tested it in ET.
- Whether CBD + THC combinations (e.g., nabiximols) work for ET. Nabiximols has been studied for tremor in multiple sclerosis, with mixed results — but MS tremor is a different condition.
- Optimal dose, route (inhaled vs. oral), and timing.
- Whether responders share any clinical or genetic features.
- Long-term safety in older ET patients, who make up most of the population.
- Interaction with primidone and propranolol at clinically relevant doses.
Comparison with standard treatments
First-line (propranolol, primidone). Both have decades of evidence and are recommended by the American Academy of Neurology guideline for ET [1]. Each reduces tremor amplitude by roughly 50% in responders, though about half of patients don't respond or can't tolerate side effects (fatigue, low blood pressure, sedation).
Second-line oral drugs. Topiramate, gabapentin, and benzodiazepines (clonazepam) have moderate evidence.
Procedural options. For severe, drug-refractory ET: deep brain stimulation (DBS) of the thalamus and MR-guided focused ultrasound (MRgFUS) thalamotomy both produce large, durable reductions in tremor [6]. These are by far the most effective interventions available.
Cannabis. Sits below all of the above in the evidence hierarchy. It is not an established alternative; at best it is an adjunct that might help some individuals, with the caveat that the one rigorous trial was negative.
Risks and interactions
- Cognitive and balance effects. Older adults (the majority of ET patients) are more sensitive to THC's effects on cognition, balance, and orthostatic blood pressure. Falls are a real concern.
- Worsening tremor. THC at higher doses can occasionally cause tremor or jitteriness, particularly in inexperienced users. Weak / limited
- Drug interactions. CBD inhibits cytochrome P450 enzymes (CYP3A4, CYP2C19, others) and can raise levels of many drugs, including some used in ET patients [7]. Primidone metabolism involves CYP enzymes; combining high-dose CBD with primidone has not been well studied.
- Cardiovascular. THC raises heart rate and can worsen orthostatic hypotension — relevant when also taking propranolol.
- Psychiatric. THC can trigger anxiety or paranoia, which may increase tremor in social situations.
- Cost and regulation. Medical cannabis is typically not insurance-covered. Product labeling — especially THC and CBD content — is frequently inaccurate in unregulated markets [8].
Not medical advice. This article summarizes published evidence for educational purposes. Decisions about treating essential tremor should be made with a qualified neurologist who knows your full medical history and medication list.
Sources
- Peer-reviewed Zesiewicz TA, et al. Evidence-based guideline update: Treatment of essential tremor. Neurology. 2011;77(19):1752-1755.
- Peer-reviewed Mainka T, et al. Cannabidiol for the treatment of essential tremor: a randomized, double-blind, placebo-controlled crossover trial. Movement Disorders Clinical Practice. 2022.
- Peer-reviewed Sengupta S, Litvan I, et al. Cannabis use in essential tremor: patient-reported outcomes. Tremor and Other Hyperkinetic Movements. 2022.
- Peer-reviewed Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiology of Disease. 1998;5(6):534-551.
- Peer-reviewed Watts S, et al. Cannabis labelling is associated with genetic variation in terpene synthase genes. Nature Plants. 2021;7:1330-1334.
- Peer-reviewed Elias WJ, et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. New England Journal of Medicine. 2016;375:730-739.
- Peer-reviewed Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine. 2019;8(7):989.
- Peer-reviewed Bonn-Miller MO, et al. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318(17):1708-1709.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.